Dihydroartemisinin-piperaquine for the routine treatment of uncomplicated malaria in Northern Ghana
Keywords:Effectiveness, Dihydroartemisinin-piperaquine, Uncomplicated malaria, Ghana
Background: Dihydroartemisinin-piperaquine is a first line treatment for uncomplicated malaria in Ghana. A facility-based study was undertaken to examine the effectiveness of the treatment in the routine health care system.
Methods: The study was undertaken at the Navrongo demographic surveillance area. Patients presenting with acute febrile illness were enrolled after informed consented and confirmation by microscopy. Patients were randomized into supervised group who received treatment under direct observation and unsupervised group which had only the first treatment given under supervision. Treatment was according to bodyweight and 42 days follow-up was undertaken.
Results: A total of 194 patients were enrolled; 54.1% were females and 51% had supervised treatment. The median age and weight were 6.7 years and 20.0 kg respectively. Mean baseline temperature, haemoglobin concentration and parasite density were, 37.6 oC, 11.1 g/dl and 11,098 parasites per microliter of blood respectively. Study completion rate was 93.3%, day 42 polymerase chain reaction-unadjusted adequate clinical and parasitological responses rate (ACPR) was 93.4% by evaluable and 87.1 % by intention-to-treat (ITT). The day 42 ACPR by evaluable was 92.3% in the supervised arm compared to 94.4% in the unsupervised arm. The day 42 ACPR by ITT was 85.7% in the supervised and 88.5% in the unsupervised arms. The fever resolution and haemoglobin concentration changes for the two arms were similar.
Conclusions: The results show that dihydroartemisinin-piperaquine is effective and good first-line antimalarial in the routine health delivery system.
World Health Organization. World malaria report 2014. World Health Organization; 2014.
Nkumama IN, O'Meara WP, Osier FHA. Changes in malaria epidemiology in Africa and new challenges for elimination. Trends Parasitol. 2017;33(2):128-40.
O'Meara WP, Mangeni JN, Steketee R, Greenwood B. Changes in the burden of malaria in sub-Saharan Africa. Lancet Infect Dis. 2010;10(8):545-55.
Moran M, Guzman J, Henderson K, Abela-Oversteegen L, Wu L, Omune B, et al. Cures P. Neglected disease research and development: Is the global financial crisis changing R&D. London: Policy Cures; 2011.
Wells TN. Natural products as starting points for future anti-malarial therapies: going back to our roots?. Malaria journal. 2011;10(1):3.
Awoonor-Williams JK, Sory EK, Nyonator FK, Phillips JF, Wang C, et al. Lessons learned from scaling up a community-based health program in the Upper East Region of northern Ghana. Glob Health sci Pract. 2013;1(1):117-33.
Nyonator FK, Awoonor-Williams JK, Phillips JF, Jones TC, Miller RA. The Ghana Community-based Health Planning and Services Initiative for scaling up service delivery innovation. Health Policy Plan. 2005;20:25-34.
World Health Organization. Guidelines for the treatment of malaria. World Health Organization; 2015.
Koram KA, Abuaku B, Duah N, Quashie N. Comparative efficacy of antimalarial drugs including ACTs in the treatment of uncomplicated malaria among children under 5 years in Ghana. Acta Tropica. 2005;95(3):194-203.
Anti-Malaria Drug Policy for Ghana, 2nd Revised Version; 2009. Available at: http://apps.who.int /medicinedocs/en/d/Js18072en/. Accessed on 18 September 2019.
Keating GM. Dihydroartemisinin/piperaquine. Drugs. 2012;172(7):937-61.
Oduro AR, Wak G, Azongo D, Debpuur C, Wontuo P, Kondayire F, et al. Profile of the Navrongo Health and Demographic Surveillance System. Int J Epidemiol. 2012;41(4):968-76.
Koram KA, Owusu-Agyei S, Fryauff DJ, Anto F, Atuguba F, Hodgson A, et al. Seasonal profiles of malaria infection, anaemia, and bednet use among age groups and communities in northern Ghana. Trop Med Int Health. 2003;8(9):793-802.
Appawu M, Owusu-Agyei S, Dadzie S, Asoala V, Anto F, Koram K, et al. Malaria transmission dynamics at a site in northern Ghana proposed for testing malaria vaccines. Trop Med Int Health. 2004;9(1):164-70.
Oduro AR, Koram KA, Rogers W, Atuguba F, Ansah P, Anyorigiya T, et al. Severe falciparum malaria in young children of the Kassena-Nankana district of northern Ghana. Malar J. 2007;6:96.
WHO. Antimalarial drug efficacy and drug resistance. Available at: http://www.who.int/malari a/areas/treatment/drug_efficacy/en/. Accessed on 18 September 2019.
Smithuis F, Kyaw MK, Phe O, Aye KZ, Htet L, Barends M, et al. Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet. 2006;367(9528):2075–85.
Gutman J, Kovacs S, Dorsey G, Stergachis A, Ter Kuile FO. Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17(2):184-93.
Sondo P, Derra K, Nakanabo SD, Tarnagda Z, Kazienga A, Valea I, et al. Comparison of effectiveness of two different artemisinin-based combination therapies in an area with high seasonal transmission of malaria in Burkina Faso. Ann Parasitol. 2017;63(2):127-31.
Kemmler G, Hummer M, Widschwendter C, Fleischhacker WW. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatr. 2005;62(12):1305-12.
Mullins CD, Shaya FT, Meng F, Wang J, Harrison D. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram. Pharmacotherapy: J Hum Pharmacol Drug Therap. 2005;25(5):660-7.
Pelagotti F, Santarlasci B, Vacca F, Trippoli S, Messori A. Dropout rates with olanzapine or risperidone: a multi-centre observational study. Europ J Clin Pharmacol. 2004;59(12):905-9.
Janssens B, van Herp M, Goubert L, Chan S, Uong S, Nong S, et al. A randomized open study to assess the efficacy and tolerability of dihydroartemisinin–piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health. 2007;12(2):251-9.
Dabhade S, Pandit P, Tiwari S, Pandit D, Chopra A. Reasons for patient’s withdrawal from clinical trials of rheumatoid arthritis in India. J Orthop Allied Sci. 2015;3(1):8.